Bortezomib in Treating Patients With Myelodysplastic Syndromes

The recruitment status of this study is unknown because the information has not been verified recently.

Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was Recruiting

Sponsor:

Information provided by:

National Cancer Institute (NCI)

ClinicalTrials.gov Identifier:

NCT00262873

First received: December 6, 2005

Last updated: July 7, 2009

Last verified: July 2009

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

No publications provided by National Cancer Institute (NCI)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, Phillips Ii GL. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer Invest. 2011 Aug;29(7):439-50.

To Top